TY - JOUR
T1 - Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy
AU - Sato, Yasufumi
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/7
Y1 - 2011/7
N2 - Angiogenesis is recognized as one of the principal hallmarks of cancers. Cancers contain newly formed immature vessels devoid of firm coverage by pericytes. Several drugs targeting vascular endothelial growth factor signals are now in clinical use for anti-angiogenic cancer treatment. Those drugs transiently normalize tumor vessels and ultimately provoke vascular regression. This regression causes tumor hypoxia, which could trigger certain cancer cells to become more invasive and metastatic. Normalized vessels do not induce tumor hypoxia, and may protect from cancer cell intravasation and enhance anticancer treatment with chemotherapeutic agents, radiation, or immune therapy. Thus, persistent vascular normalization could be an alternative goal of anti-angiogenic cancer treatment.
AB - Angiogenesis is recognized as one of the principal hallmarks of cancers. Cancers contain newly formed immature vessels devoid of firm coverage by pericytes. Several drugs targeting vascular endothelial growth factor signals are now in clinical use for anti-angiogenic cancer treatment. Those drugs transiently normalize tumor vessels and ultimately provoke vascular regression. This regression causes tumor hypoxia, which could trigger certain cancer cells to become more invasive and metastatic. Normalized vessels do not induce tumor hypoxia, and may protect from cancer cell intravasation and enhance anticancer treatment with chemotherapeutic agents, radiation, or immune therapy. Thus, persistent vascular normalization could be an alternative goal of anti-angiogenic cancer treatment.
UR - http://www.scopus.com/inward/record.url?scp=79959236558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959236558&partnerID=8YFLogxK
U2 - 10.1111/j.1349-7006.2011.01929.x
DO - 10.1111/j.1349-7006.2011.01929.x
M3 - Review article
C2 - 21401807
AN - SCOPUS:79959236558
VL - 102
SP - 1253
EP - 1256
JO - Cancer Science
JF - Cancer Science
SN - 1347-9032
IS - 7
ER -